I haven't researched it at all..the company website indicates the benefit is primarily related to more limited tissue distribution of the receptor and hence the potential for improved side effect profile. A quick pubmed search shows quite a body of preclinical data suggesting comparable efficacy to interferon alpha..while it will likely be developed as a replacement for peg-alpha, the MOA is quite distinct and in a replicon model the two interferons demonstrate synergy (so in theory at least it might actually boost efficacy as an add-on therapy - although I can't imagine any human being able to tolerate more interferon than current SOC)
Market Data 
Markets 
AI
